Harbor MedTech Inc. in Irvine raised $5 million in equity funding from three investors as part of an unfinished $8.5 million effort, a regulatory filing said.
The company develops tissue regeneration products from live sources—collagen protein, biologic substrates and xenografts—for chronic wounds and for hernia and joint repair.
It says its approach improves compatibility and speeds regeneration in tissue grafts and tissue growth.
Harbor MedTech’s first two products are Architect, which treats skin wounds, and EPMatrix, which treats soft-tissue injuries.
The company earlier raised $4.3 million in venture backing, according to Crunchbase.
—Paul Hughes
